EP0930891A4 - Orale verabreichung von antikoerpern aus huehnereigelb zur behandlung von krankheiten - Google Patents

Orale verabreichung von antikoerpern aus huehnereigelb zur behandlung von krankheiten

Info

Publication number
EP0930891A4
EP0930891A4 EP97909921A EP97909921A EP0930891A4 EP 0930891 A4 EP0930891 A4 EP 0930891A4 EP 97909921 A EP97909921 A EP 97909921A EP 97909921 A EP97909921 A EP 97909921A EP 0930891 A4 EP0930891 A4 EP 0930891A4
Authority
EP
European Patent Office
Prior art keywords
oral administration
treat disease
yolk antibodies
chicken yolk
chicken
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97909921A
Other languages
English (en)
French (fr)
Other versions
EP0930891A1 (de
Inventor
Marilyn A Coleman
Mitchell V Kaminski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovimmune Inc
Original Assignee
Ovimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovimmune Inc filed Critical Ovimmune Inc
Publication of EP0930891A1 publication Critical patent/EP0930891A1/de
Publication of EP0930891A4 publication Critical patent/EP0930891A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97909921A 1996-10-02 1997-10-02 Orale verabreichung von antikoerpern aus huehnereigelb zur behandlung von krankheiten Withdrawn EP0930891A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72440896A 1996-10-02 1996-10-02
US724408 1996-10-02
PCT/US1997/017722 WO1998014209A1 (en) 1996-10-02 1997-10-02 Oral administration of chicken yolk antibodies to treat disease

Publications (2)

Publication Number Publication Date
EP0930891A1 EP0930891A1 (de) 1999-07-28
EP0930891A4 true EP0930891A4 (de) 2001-07-04

Family

ID=24910322

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97909921A Withdrawn EP0930891A4 (de) 1996-10-02 1997-10-02 Orale verabreichung von antikoerpern aus huehnereigelb zur behandlung von krankheiten

Country Status (7)

Country Link
EP (1) EP0930891A4 (de)
JP (1) JP2001501622A (de)
KR (1) KR20000048855A (de)
AU (1) AU729502B2 (de)
CA (1) CA2267421A1 (de)
NZ (1) NZ335170A (de)
WO (1) WO1998014209A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
US7494652B1 (en) * 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
DE19910159A1 (de) * 1999-02-26 2000-09-14 Rosemarie Heis Spezifische lgY-Eidotterantikörper, ihre Gewinnung und ihre Verwendung
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7355092B2 (en) 1999-12-27 2008-04-08 Ronald Marquardt Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens
KR100364198B1 (ko) * 2000-06-09 2002-12-12 영농조합법인다한 헬리코박터 파이로리에 대한 개선된 ｌｇＹ 생성의유도방법 및 이에 의해 제조된 계란
CA2437095A1 (en) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for modulating the immune system of animals
BR0206869A (pt) * 2001-01-30 2007-01-02 Lauridsen Group Inc método para o tratamento de um animal sofrendo de um estado doentio de disfunção imune associado com nìveis alterados de igg ou tnf-delta, composição farmacêutica para o tratamento de distúrbios auto-imunes associados com elevados igg e/ou tnf-delta ou para a potenciação de protocolos de vacina, e método para o tratamento de estado doentio associado com disfunção imune em um animal
CA2339436A1 (fr) * 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
KR20030026502A (ko) * 2001-09-26 2003-04-03 배만종 다기능성(抗헬리코박터 파이롤리 항체, 저콜레스테롤,高디에이취에이 함유) 일반계란, 토종계란 및 청색계란생산방법
KR100392566B1 (ko) * 2001-11-13 2003-07-23 주식회사 에그 바이오택 여드름질환에 관한 프로피오니박테리움 아크네스, 스타필로코커스 에피더미디스, 대장균에 대한 항-혼합균 공유 복합특수면역단백질(IgY) 함유 계란생산 및 항-혼합균 공유 복합특수면역단백질(IgY) 제조방법
CA2438698C (en) * 2001-12-28 2013-12-17 Camas, Incorporated Immunogen adherence inhibitor and method of making and using same
KR100489615B1 (ko) * 2002-01-30 2005-05-17 주식회사 단바이오텍 리스테리아 모노사이토제네스 감염의 예방 및 치료를 위한항체, 이를 포함하는 알 및 이들의 제조방법
KR20030079382A (ko) * 2002-04-04 2003-10-10 최태부 소화 효소-지방산 복합체를 항원으로하여 생산된 항체 및이의 이용
WO2003105873A1 (ja) * 2002-06-13 2003-12-24 株式会社 トーカイビケン テイラーメイド製剤及びその製造方法
KR20040005540A (ko) * 2002-07-10 2004-01-16 백반석 장염과 식중독의 원인물질에 대한 복합 특이 난황 항체의생산 방법
KR20040005539A (ko) * 2002-07-10 2004-01-16 백반석 이온수와 당을 이용한 계란 난황내의 수용성 특수면역단백질의 분리 및 제조
KR20040005541A (ko) * 2002-07-10 2004-01-16 선우선영 여드름 원인물질에 대한 효과적인 여러형태의 복합특이난황항체의 생산법
ES2393674T3 (es) * 2003-11-14 2012-12-27 Brigham And Women's Hospital, Inc. Métodos para modular la inmunidad
WO2005099753A1 (en) * 2004-04-16 2005-10-27 The Govenors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
EP1723951A1 (de) * 2005-04-21 2006-11-22 N.V. Nutricia Nahrungsergänzungspräparat mit Oligosacchariden für eine Kategorie von HIV Patienten
JP2007084495A (ja) * 2005-09-22 2007-04-05 Daikin Ind Ltd ウイルス感染細胞処理方法
JP2007082486A (ja) * 2005-09-22 2007-04-05 Daikin Ind Ltd ウイルスが感染した生物由来物の処理方法、感染ウイルスに対する処理済細胞、感染ウイルスに対する処理済組織、感染ウイルスに対する処理済臓器
NZ575918A (en) * 2006-08-31 2012-03-30 A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Treatment and/or prevention of non-infectious medical conditions using antibody-containing milk or egg products
WO2008051980A2 (en) 2006-10-25 2008-05-02 Wisconsin Alumni Research Foundation Methods of reducing phosphate absorption
US8282928B2 (en) 2007-05-30 2012-10-09 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
ES2742734T3 (es) 2010-11-23 2020-02-17 Pantheryx Inc Composiciones y procedimientos para el tratamiento en aplicaciones clínicas de espectro general, no diferenciadas o mixtas
US20130011410A1 (en) * 2011-07-07 2013-01-10 Amicus Biotech Inc. Egg White Antibodies for Prevention and Treatment of Specific Localized Intestinal Infections and Diseases Associated with a Pathogenic Organism or Molecule
KR101911229B1 (ko) 2011-08-19 2018-10-24 임모탈 스피릿 리미티드 항체 및 항체 함유 조성물
CN106749650B (zh) * 2016-12-19 2021-06-25 姚善龙 抗感冒病毒及肺链菌、葡萄球菌复合IgY抗体制备方法及其应用
KR102200721B1 (ko) * 2019-11-18 2021-01-13 (주)애드바이오텍 연어 리케차성 패혈증 예방 또는 치료용 난황항체의 제조방법
CN112957464A (zh) * 2021-02-24 2021-06-15 江秀坤 一种将鸡卵黄免疫球蛋白制备成润喉保健产品的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19504755A1 (de) * 1995-02-02 1996-08-08 Panagiotis Tsolkas Aviäre, vitelline, gegen HIV-Antigene gerichtete Antikörper
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US5258178A (en) * 1990-07-30 1993-11-02 Abbott Laboratories Method and product for the treatment of gastric disease
US5420253A (en) * 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
DE19504755A1 (de) * 1995-02-02 1996-08-08 Panagiotis Tsolkas Aviäre, vitelline, gegen HIV-Antigene gerichtete Antikörper

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERTEL R ET AL: "Formation of antibodies to prostaglandins in the yolk of chicken eggs.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1981 OCT 15) 102 (3) 1028-33., XP000984898 *
See also references of WO9814209A1 *

Also Published As

Publication number Publication date
AU4741997A (en) 1998-04-24
EP0930891A1 (de) 1999-07-28
AU729502B2 (en) 2001-02-01
KR20000048855A (ko) 2000-07-25
JP2001501622A (ja) 2001-02-06
WO1998014209A1 (en) 1998-04-09
NZ335170A (en) 2001-08-31
CA2267421A1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
EP0930891A4 (de) Orale verabreichung von antikoerpern aus huehnereigelb zur behandlung von krankheiten
GB9401520D0 (en) Treatment of poultry
IL121894A (en) Process for the preparation of a protein composition from animal muscle tissue
PL335974A1 (en) Method of orally administering proteins
NO995134L (no) Forbedrede fremgangsmåter for fremstilling av aktivert protein C
EP0979647A4 (de) Fettemulsion zur oralen verabreichung
KR970000228A (ko) S-에토돌락의 경구용 제제
ZA931489B (en) Use of interleuken-10 to suppress graft-vs-host disease
AU2340397A (en) Use of nicotine to treat liver disease
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
TR199701051A3 (tr) 2' -Fluoro-5-metil- -l-arabino-furanosilüridin hazirlanma prosesi
PL337064A1 (en) Method of and compositions for orally administering taxanes to human beings
HUP0001263A3 (en) Methods of therapeutic administration of anti-cd4ol compounds
IL117668A0 (en) Preparation of polyesters
IL115307A (en) Modification of egg composition by chicken feed supplements and the resulting eggs obtained
ZA969147B (en) Application of the gax protein to the treatment of cancer
AU8185491A (en) Treatment of disease
GB9801142D0 (en) Administration of beneficial substances to ruminant animals
HUP9801925A3 (en) Use of sodium-hydrogen-exchange-inhibitors for producing pharmaceutical compositions treating diseases caused by protozoons
AU7492087A (en) Newcastle disease virus protein
EP0755262A4 (de) Zubereitung für die behandlung von lungenerkrankungen
IL119282A0 (en) Treatment of fowl
AU7712598A (en) Lipid-reduced oral formulation for egg yolk-derived therapeutic protein
ZA97210B (en) Oral administration of effective amunts of forms of hyaluronic acid
IL114923A0 (en) Chintin extract for treatment of skin disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990414

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010518

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030503